

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 7, 2008
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 7, 2008.

2. Welcome

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Mrs. Forkner thanked the committee for their service. She provided an update on the status of the budget for Medicaid for next fiscal year. The status of the budget for next year is in legislation and cuts are expected.

3. Committee Members Present:

Ed Behling, M.D.

Joe Horvath, M.D.

Tan Platt, M..D.

Jody Bolinger, M..D.

Kelly Jones, Pharm.D.

Charles Raine, M..D.

Greg Browning, M.D.

Jim Lindsay, M.D.

Debbie Tapley, R.Ph.

Charmaine George, M.D.

George E. Vess, Pharm. D.

DHHS Staff Present:

Emma Forkner, Medicaid Director

Felicity Meyers, Deputy Director

James M Assey, R.Ph.

Mike Blakely, R.Ph.

Deidra Singleton, J.D.

Byron Roberts, J.D.

April Smith

Other Representation:

First Health Services. – Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 6, 2007.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Astra Zeneca	Sonja Grooms-Smith Ph.D.	Crestor®
Pfizer	Henry Martin, M.D.	Lipitor®
Merck/Schering Plough	Green B. Neal, M.D.	Vytorin®
Abbott	Green B. Neal, M.D.	Niaspan®
Abbott	Green B. Neal, M.D.	Simcor®
Sanofi Aventis	Jeffrey Harless, Ph.D.	Allegra® Oral Suspension
Sanofi Aventis	Jeffrey Harless, Ph.D.	Xyzal®
Actelion	Karen Ward, Pharm.D.	Tracleer®
Gilead	Muhammed Ali Raza, M.D.	Letairis®
Shire US	Spencer Jenkins, M.D.	Lialda®
Glaxo Smith Kline	Michelle Welch, M.D.	Altabax®
Pfizer	Mark Lencke, M.D.	Lyrica®
UCB Pharma	Nigel Isaacs, J.D., Pharm.D.	Keppra®
Abbott	Christine Vaupel, M.D.	Lamictal®
Public Comment	Barbara Brothers, Director, Epilepsy Foundation of South Carolina	Anticonvulsants

C. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- High Potency Statins/Cholesterol Absorption Inhibitors
- Niacin Derivatives and Statin Combinations
- Low Sedating Antihistamines
- Low Sedating Antihistamine/Decongestant Combinations
- Endothelin Receptor Antagonists
- Ulcerative Colitis Therapy – Oral, Rectal
- Topical Antibiotics
- Serotonin Receptor Agonists
- First Generation Anticonvulsants
- Second Generation Anticonvulsants

The chart below represents the recommendations from the P & T Committee:

<i>High Potency Statins/Cholesterol Absorption Inhibitors</i>	
NO PA REQUIRED “PREFERRED”	PA REQUIRED
SIMVASTATIN CRESTOR®* LIPITOR®*	VYTORIN® ZETIA® ZOCOR®

* Crestor® and Lipitor® preferred with a step edit to look for simvastatin in patient history

<i>Niacin Derivatives and Statin Combinations</i>	
NO PA REQUIRED “PREFERRED”	PA REQUIRED
ADVICOR® NIASPAN® SIMCOR®	NIACOR®

<i>Low Sedating Antihistamines</i>	
NO PA REQUIRED “PREFERRED”	PA REQUIRED
LORATADINE ZYRTEC®	ALLEGRA® CLARITIN® CLARINEX® FEXOFENADINE XYZAL®

*Allegra Oral Suspension allowed with a step edit to look for loratadine or Zyrtec® in 30 days of history

<i>Low Sedating Antihistamine/Decongestant Combinations</i>	
NO PA REQUIRED “PREFERRED”	PA REQUIRED
LORATADINE D ZYRTEC D®	ALLEGRA D® CLARITIN D® CLARINEX D®

<i>Endothelin Receptor Antagonists</i>	
NO PA REQUIRED “PREFERRED”	PA REQUIRED
TRACLEER®	LETAIRIS®

*Patients currently on Letairis® will be grandfathered.

Ulcerative Colitis Therapy - Oral

NO PA REQUIRED "PREFERRED"	PA REQUIRED
ASACOL® BALSALAZIDE DISODIUM PENTASA® SULFASALAZINE	COLAZAL® DIPENTUM® LIALDA®

Ulcerative Colitis Therapy – Rectal

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CANASA® RECTAL SUPPOSITORIES MESALAMINE ENEMA	

Topical Antibiotics

NO PA REQUIRED "PREFERRED"	PA REQUIRED
MUPIROCIN ALTABAX® BACTROBAN® CREAM	BACTROBAN® OINTMENT

Serotonin Receptor Agonists

NO PA REQUIRED "PREFERRED"	PA REQUIRED
IMITREX® (ALL DOSAGE FORMS) TREXIMET®	AMERGE® AXERT® FROVA® MAXALT® MAXALT MLT® RELPAK® ZOMIG® ZOMIG ZMT®

First Generation Anticonvulsants

NO PA REQUIRED "PREFERRED"	PA REQUIRED
CELONTIN® DEPAKOTE® DEPAKOTE ER® DEPAKOTE SPRINKLE® ETHOSUXIMIDE FELBATOL® MEBARAL® PHENYTOIN PHENYTOIN SODIUM EXTENDED RELEASE PRIMIDONE VALPROIC ACID	DEPAKENE® DILANTIN®* MYSOLINE® PHENYTEK® ZARONTIN®

*Dilantin® is a narrow therapeutic agent and falls under the "Brand Medically Necessary" Policy addressed in the Medicaid Pharmacy Services Provider Manual.

Second Generation Anticonvulsants

NO PA REQUIRED "PREFERRED"	PA REQUIRED
GABAPENTIN KEPPRA® LAMICTAL® LAMOTRIGINE LYRICA® TOPAMAX® ZONISAMIDE	GABITRIL®* NEURONTIN® ZONEGRAN®

*Patients currently on Gabitril® will be grandfathered.

5. **Old Business**

6. **New Business**

Debbie Tapley announced the classes for review at the August Meeting:

Oral Quinolones

Long Acting Narcotics

Nasal Steroids

Sedative Hypnotics

Prostaglandin Ophthalmics

Hematopoietics

Platelet Inhibitors

Ophthalmic NSAIDs

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

High Potency Statins/Cholesterol Absorption Inhibitors

Niacin Derivatives and Statin Combinations

Low Sedating Antihistamines

Low Sedating Antihistamine/Decongestant Combinations

Endothelin Receptor Antagonists

Ulcerative Colitis Therapy – Oral, Rectal

Topical Antibiotics

Serotonin Receptor Agonists

First Generation Anticonvulsants

Second Generation Anticonvulsants

8. **Closing Comments**

The next meeting will be held on Wednesday, August 6, 2008 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 6:55 p.m.